Carol Sherman to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Carol Sherman has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
1.348
-
Conformal high dose external radiation therapy, 80.5 Gy, alone for medically inoperable non-small cell lung cancer: a retrospective analysis. J Thorac Oncol. 2006 Feb; 1(2):112-9.
Score: 0.211
-
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004 Sep; 45(3):387-92.
Score: 0.191
-
The treatment of limited small cell lung cancer: a report of the progress made and future prospects. Eur J Cancer. 2002 Jan; 38(2):279-91.
Score: 0.159
-
Radiation and chemotherapy for patients with stage III non-small cell lung cancer. Semin Radiat Oncol. 2000 Oct; 10(4):289-95.
Score: 0.145
-
ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2018 05; 19(5):694-704.
Score: 0.122
-
Imaging in Advanced Non-Small Cell Lung Cancer: A Medical Oncology Perspective. J Thorac Imaging. 2016 Jul; 31(4):238-42.
Score: 0.108
-
Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015 Feb; 10(2):232-6.
Score: 0.098
-
The role of molecular analyses in the era of personalized therapy for advanced NSCLC. Lung Cancer. 2012 May; 76(2):131-7.
Score: 0.079
-
Lunx is a superior molecular marker for detection of non-small cell lung cancer in peripheral blood [corrected]. J Mol Diagn. 2003 Nov; 5(4):237-42.
Score: 0.045
-
The role of radiotherapy and chemotherapy for curative management of medically inoperable and stage III nonsmall cell lung cancer, and radiotherapy for palliation of symptomatic disease. Respir Care Clin N Am. 2003 Jun; 9(2):163-90.
Score: 0.044
-
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003 May 15; 97(10):2480-6.
Score: 0.044
-
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative. Oncology (Williston Park). 2000 Jul; 14(7 Suppl 4):7-14.
Score: 0.036
-
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer. Semin Oncol. 1999 Oct; 26(5 Suppl 16):43-50; discussion 71-2.
Score: 0.034
-
The 1997 International Staging System for non-small cell lung cancer: have all the issues been addressed? Chest. 1999 Jan; 115(1):242-8.
Score: 0.032